These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35293322)

  • 1. The intrapleural administration with thymic peptides in malignant pleural effusion: A clusteredsystematicreview and meta-analysis.
    Wang CQ; Shen YS; Chen XF; Jiang H; Yang XM; Fan TY; Li SG; Yang P; Zhan L; Chen R; Feng JH; Xiao X; Xiao Z
    Int Immunopharmacol; 2022 Jun; 107():108688. PubMed ID: 35293322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evidence framework of traditional Chinese medicine injection (Aidi injection) in controlling malignant pleural effusion: A clustered systematic review and meta-analysis.
    Wang CQ; Xu J; Jiang H; Zheng XT; Zhang Y; Huang XR; She F; Fan TY; Zhan L; Feng JH; Gong QH; Xiao X; Chen XF; Xiao Z
    Phytomedicine; 2023 Jul; 115():154847. PubMed ID: 37149965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrapleural Perfusion With Staphylococcal Enterotoxin C for Malignant Pleural Effusion: A Clustered Systematic Review and Meta-Analysis.
    Jiang H; Yang XM; Wang CQ; Xu J; Huang J; Feng JH; Chen XF; Chen K; Zhan L; Xiao X; Xiao Z
    Front Med (Lausanne); 2022; 9():816973. PubMed ID: 35547209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B.
    Noro R; Kobayashi K; Usuki J; Yomota M; Nishitsuji M; Shimokawa T; Ando M; Hino M; Hagiwara K; Miyanaga A; Seike M; Kubota K; Gemma A;
    Thorac Cancer; 2020 Jul; 11(7):1876-1884. PubMed ID: 32421226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer.
    Ren S; Terman DS; Bohach G; Silvers A; Hansen C; Colt H; Sahn SA
    Chest; 2004 Nov; 126(5):1529-39. PubMed ID: 15539723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrapleural Administration With Rh-Endostatin and Chemical Irritants in the Control of Malignant Pleural Effusion: A Systematic Review and Meta-Analysis.
    Wang CQ; Huang XR; He M; Zheng XT; Jiang H; Chen Q; Fan TY; Zhan L; Ling J; Feng JH; Xiao X; Chen XF; Xiao Z
    Front Oncol; 2021; 11():649999. PubMed ID: 34414103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrathoracic infusion therapy with Lentinan and chemical irritants for malignant pleural effusion: a systematic review and meta-analysis of 65 randomized controlled trials.
    Xiao Z; Jiang Y; Chen XF; Wang CQ; Zheng XT; Xu WH; Zou XX; Zhou JM; Yang YH; Hu SS; Shan LJ; Cai QY; Tang YH; Feng JH; Xiao X
    Phytomedicine; 2020 Jun; 76():153260. PubMed ID: 32535483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of medical thoracoscopy-guided intrapleural docetaxel therapy to manage malignant pleural effusion in patients with non-small cell lung cancer: A pilot study.
    Choi MG; Park S; Oh DK; Kim HR; Lee GD; Lee JC; Choi CM; Ji W
    Thorac Cancer; 2019 Oct; 10(10):1885-1892. PubMed ID: 31389192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The effect of intrapleural pingyangmycin administration on activity of fibrinolytic system and transforming growth factor-beta1 in malignant pleural effusion].
    Zhu QQ; Sun GY
    Zhonghua Jie He He Hu Xi Za Zhi; 2009 Sep; 32(9):674-8. PubMed ID: 20079281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrapleural paclitaxel for malignant pleural effusion from ovarian and breast cancer: a phase II study with pharmacokinetic analysis.
    Lombardi G; Nicoletto MO; Gusella M; Fiduccia P; Dalla Palma M; Zuin A; Fiore D; Donach M; Zagonel V
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):781-7. PubMed ID: 22037881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer‑mediated malignant pleural effusion.
    Du N; Li X; Li F; Zhao H; Fan Z; Ma J; Fu Y; Kang H
    Oncol Rep; 2013 Jun; 29(6):2332-40. PubMed ID: 23525453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A.
    Usui K; Sugawara S; Nishitsuji M; Fujita Y; Inoue A; Mouri A; Watanabe H; Sakai H; Kinoshita I; Ohhara Y; Maemondo M; Kagamu H; Hagiwara K; Kobayashi K;
    Lung Cancer; 2016 Sep; 99():131-6. PubMed ID: 27565928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Impact of intrapleural hyperthermic perfusion on immunologic reaction state of cytokines TH1/TH2 of lung carcinoma patients with malignant pleural effusion].
    Kang MQ; Cao YP; Deng F
    Ai Zheng; 2008 Feb; 27(2):210-3. PubMed ID: 18279624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced malignant pleural effusion.
    Tao H; Meng Q; Li M; Shi L; Tang J; Liu Z
    Thorac Cancer; 2018 Feb; 9(2):298-304. PubMed ID: 29297985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.
    Chen D; Li X; Zhao H; Fu Y; Yao F; Hu J; Du N
    Indian J Cancer; 2014 Mar; 51 Suppl 3():e82-5. PubMed ID: 25818740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of intrapleural hyperthermic perfusion in patients with malignant pleural effusion undergoing video-assisted thoracic surgery: a single-arm clinical trial.
    Wang X; Kong M; Jin J; Lin Y; Jia L; Ye M
    J Thorac Dis; 2022 May; 14(5):1497-1503. PubMed ID: 35693629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival in patients with malignant pleural effusion undergoing talc pleurodesis.
    Hassan M; Mercer RM; Maskell NA; Asciak R; McCracken DJ; Bedawi EO; Shaarawy H; El-Ganady A; Psallidas I; Miller RF; Rahman NM
    Lung Cancer; 2019 Nov; 137():14-18. PubMed ID: 31521977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion.
    Kitamura K; Kubota K; Ando M; Takahashi S; Nishijima N; Sugano T; Toyokawa M; Miwa K; Kosaihira S; Noro R; Minegishi Y; Seike M; Yoshimura A; Gemma A
    Cancer Chemother Pharmacol; 2013 Feb; 71(2):457-61. PubMed ID: 23178954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of Viscum album extract (Helixor-M) to treat malignant pleural effusion in patients with lung cancer.
    Lee YG; Jung I; Koo DH; Kang DY; Oh TY; Oh S; Lee SS
    Support Care Cancer; 2019 May; 27(5):1945-1949. PubMed ID: 30218188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Talc pleurodesis as surgical palliation of patients with malignant pleural effusion. Analysis of factors affecting survival.
    Lumachi F; Mazza F; Ermani M; Chiara GB; Basso SM
    Anticancer Res; 2012 Nov; 32(11):5071-4. PubMed ID: 23155281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.